Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772053 · ClinicalTrials.gov registry record · Phase 2
Molecular Disease Characterization Initiative (MDCI)
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04772053 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 6 participants.
The verdict
NCT04772053, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a single arm interventional molecular analysis study with no administration of investigational product and no masking. This multicenter study will involve participants with advanced/metastatic disease for the purpose of collecting tumor tissue and blood samples for broad molecular analysis and examining the expression of specific biomarkers using validated clinical assays.
Interventions
- PROCEDURE Tumor biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04772053
The ClinicalTrials.gov registry entry for NCT04772053 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tumor biopsy is the first listed.
NCT04772053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04772053 about?
NCT04772053 is a clinical study titled "Molecular Disease Characterization Initiative (MDCI)". This is a single arm interventional molecular analysis study with no administration of investigational product and no masking. This multicenter study will involve participants with advanced/metastatic disease for the purpose of collecting tumor tissue and blood samples for broad molecular analysis a...
What is the current status of trial NCT04772053?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-05-25. Estimated completion is 2022-11-15.
What interventions are being tested in trial NCT04772053?
The interventions under investigation include: Tumor biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT04772053?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.